MRS of oligodendroglial tumors - Correlation with histopathology and genetic subtypes

被引:31
作者
Jenkinson, MD [1 ]
Smith, TS
Joyce, K
Fildes, D
du Plessis, DG
Warnke, PC
Walker, C
机构
[1] Univ Liverpool, Ctr Clin Sci, Dept Neurol Sci, Liverpool L9 7LJ, Merseyside, England
[2] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool, Merseyside, England
[3] Walton Ctr Neurol & Neurosurg, Dept Neuroradiol, Liverpool, Merseyside, England
[4] Hope Hosp, Dept Neuropathol, Salford M6 8HD, Lancs, England
[5] Clatterbridge Hosp, JK Douglas Labs, Clatterbridge Canc Res Trust, Wirral, Merseyside, England
关键词
D O I
10.1212/01.WNL.0000165998.73779.D9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Oligodendroglial neoplasms with combined loss of chromosomes 1p and 19q may have a good prognosis and respond to procarbazine-lomustine (CCNU)- vincristine (PCV) chemotherapy. Objective: To determine whether single voxel magnetic resonance spectroscopy (SV- MRS) obtained through routine clinical practice distinguishes between histopathologic and genetic subtypes of oligodendroglial tumors. Methods: Forty- eight patients with oligodendroglial tumors (19 oligodendrogliomas and 29 oligoastrocytomas) underwent molecular genetic analysis to determine allelic imbalance in chromosomes 1p36 and 19q13. SV- MRS was obtained pretherapy to determine tumor metabolite ratios. Results: Grade III oligodendroglial tumors had higher choline (Mann - Whitney; p = 0.002), methyl lipid (Mann - Whitney; p = 0.002), and combined methylene lipid and lactate ratios (Mann - Whitney; p < 0.001) than grade II tumors. Lactate did not distinguish between tumor types (Fisher exact test; p = 0.342) or grade (Fisher exact test; p = 0.452). There were no significant associations when tumors were analyzed according to histopathology or genetic subtypes. Conclusion: As a noninvasive diagnostic tool used in routine clinical practice, SV- MRS has the potential benefit of determining oligodendroglial tumor grade but not subtypes classified by histopathology or molecular genetics. MRS may be useful for determining the timing of therapy but is unlikely to predict chemosensitivity.
引用
收藏
页码:2085 / 2089
页数:5
相关论文
共 30 条
[1]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[2]  
Barba I, 1999, CANCER RES, V59, P1861
[3]  
BENSIRA L, 2002, NEUROONCOLOGY S1, V4, pS9
[4]  
Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034
[5]  
Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52
[6]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[7]  
Castillo M, 2000, AM J NEURORADIOL, V21, P1645
[8]   1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma:: Implications for the in vivo detection of apoptosis [J].
Hakumäki, JM ;
Poptani, H ;
Sandmair, AM ;
Ylä-Herttuala, S ;
Kauppinen, RA .
NATURE MEDICINE, 1999, 5 (11) :1323-1327
[9]   Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction [J].
Isobe, T ;
Matsumura, A ;
Anno, I ;
Yoshizawa, T ;
Nagatomo, Y ;
Itai, Y ;
Nose, T .
MAGNETIC RESONANCE IMAGING, 2002, 20 (04) :343-349
[10]   The role of stereotactic biopsy in the management of gliomas [J].
Kondziolka, D ;
Lunsford, LD .
JOURNAL OF NEURO-ONCOLOGY, 1999, 42 (03) :205-213